ReviewCureus2025
Flavoured Vaping Products in Tobacco Harm Reduction: A Regulatory Perspective.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reducing the harms associated with cigarette smoking is a global public health priority. Both the individual‑ and population‑level health impacts of smoking can be reduced by novel products which deliver nicotine, but the use of which decreases user exposure to the harmful chemical toxicants responsible for smoking‑related disease. Electronic vaping products (EVP) heat a flavoured liquid, most commonly containing nicotine, to generate an inhalable aerosol. Smokers who switch exclusively to using EVP reduce their exposure to the harmful toxicants found in cigarette smoke, and increasing evidence supports that EVP can help smokers quit smoking and support tobacco harm reduction (THR) efforts. However, concerns are being raised regarding the use of EVP among those for whom they are not intended, particularly youth, which could mitigate their THR potential. Some of this concern is attributed to the use of non‑tobacco flavours in EVP, and there have been many calls to ban the use of such flavours. The aim of this review is to examine the recent scientific literature concerning non‑tobacco flavours in EVP, focussing on the potential toxicological impact of these flavours, whether flavours affect abuse liability/dependence potential and whether they support switching away from cigarette smoking, unintended use of flavoured EVP, and the impact of existing bans and the effect of regulation. Overall, we find that non‑tobacco flavoured EVP are not of a greater risk to health and have no greater abuse liability than tobacco flavoured EVP. There is some evidence that flavoured EVP may support switching among adult smokers, while unintended use may be experimental and may not translate into long‑term use or act as a 'gateway' into smoking. Current flavour bans have been largely ineffective in modifying use behaviour and may have unintended consequences such as increasing smoking prevalence and promoting illicit trade. Overall, the population‑level THR benefit of flavoured EVP, in terms of reducing smoking rates, largely outweighs the risks associated with unintended use. Maintaining flavour diversity is an important consideration when putting in place regulatory frameworks that aim to maximise the switching benefit for adult smokers and improve overall population‑level public health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.